Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Mark Massaro - BTIG Tejas Savant - Morgan Stanley Evie Koslosky - Goldman Sachs Matt Larew - William Blair Brendan Smith - TD Cowen Operator [Call Starts Abruptly] live on air. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $3.20 per share a year ago.
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $7.37, representing a -0.14% change from its previous close.
Ginkgo Bioworks Holdings, Inc. (DNA) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.60, marking a +0.8% move from the previous day.
23andMe probe launched to prevent customer DNA data from being sold to China or other bad actors
Sen. Bill Cassidy is probing 23andMe, which recently filed for bankruptcy protection, to ensure the company does not sell customer data to China or other foreign adversaries.
What's next for 23andMe and all that DNA data?
As 23AndMe files for bankruptcy, customers are left wondering what happens to their DNA data? On this episode of the Big Take podcast, we discuss what this means for millions of users' genetic data and for the future of the genetic testing industry.
Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
23andMe bankruptcy: With America's DNA put on sale, market panic gets a new form of testing
The bankruptcy of consumer genetics testing company 23andMe last week led to widespread fears about the DNA of millions of Americans going on sale to the highest bidder. 23andMe has 15 million customers and with calls for users to delete their data, traffic to its website surged 526% on the day of its bankruptcy filing.
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.
23andMe goes bankrupt, will now auction off DNA data
23andMe has proposed a May 14 auction for the sale of its assets, which include the genetic data of more than 15 million customers. The sale of genetic data raises concerns about privacy and safety, and customers are worried about what this means for their personal information.
23andMe has filed for bankruptcy. What does this mean for your DNA data privacy?
The genetic testing company 23andMe has filed for bankruptcy, prompting people who've used the service and sent in DNA samples to be analyzed to wonder what will happen to their genetic data.
DNA testing pioneer 23andMe files for bankruptcy as concerns mount over data privacy of 15M customers
DNA testing pioneer 23andMe filed for bankruptcy — sparking fresh concerns about safeguarding the personal data of the company's more than 15 million customers.
